PKM Knockout A-549 Cell Line
Cat.No.:
EDC90635
Species:
Human
Cell Name:
A-549
Gene:
PKM1
Gene ID:
5315
Size:
1×10⁶cells
PKM1 Knockout Cell Line (A549) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC90635 |
|---|---|
| Product Name | PKM Knockout A-549 Cell Line |
| Cell line | A-549 |
| Cellosaurus ID | CVCL_0023 |
| Cell Line Synonyms | A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549 |
| Gene | PKM1 |
| NCBI Gene ID | |
| Summary |
This gene encodes a protein involved in glycolysis. The encoded protein is a pyruvate kinase that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate to ADP, generating ATP and pyruvate. This protein has been shown to interact with thyroid hormone and may mediate cellular metabolic effects induced by thyroid hormones. This protein has been found to bind Opa protein, a bacterial outer membrane protein involved in gonococcal adherence to and invasion of human cells, suggesting a role of this protein in bacterial pathogenesis. Several alternatively spliced transcript variants encoding a few distinct isoforms have been reported. [provided by RefSeq, May 2011]
|
| Associated Diseases | Non-Small Cell Lung Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5-1/4 ,2days |
| Complete Culture Medium | F-12K + 10% FBS |
| Freezing Medium | 95% Complete culture medium + 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: A-549 | STR Info (Cell bank) Cell Line: A-549 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | Y | X | Y |
| CSF1PO | 10 | 12 | 10 | 12 |
| D2S1338 | 24 | 24 | ||
| D3S1358 | 16 | 16 | ||
| D5S818 | 11 | 11 | ||
| D7S820 | 8 | 11 | 8 | 11 |
| D8S1179 | 13 | 14 | 13 | 14 |
| D13S317 | 11 | 11 | ||
| D16S539 | 11 | 12 | 11 | 12 |
| D18S51 | 14 | 17 | 14 | 17 |
| D19S433 | 13 | 13 | ||
| D21S11 | 29 | 29 | ||
| FGA | 23 | 23 | ||
| Penta D | 9 | 9 | ||
| Penta E | 7 | 11 | 7 | 11 |
| TH01 | 8 | 9.3 | 8 | 9.3 |
| TPOX | 8 | 11 | 8 | 11 |
| vWA | 14 | 14 | ||
| D6S1043 | 11 | 13 | ||
| D12S391 | 18 | 18 | ||
| D2S441 | 10 | 13 | 10 | 13 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Is this PKM Knockout A-549 Cell Line compatible with overexpression rescue experiments?
Yes, and rescue experiments are uniquely valuable for isoform-specific studies:
• Construct design: use codon-modified PKM1 or PKM2 isoform-specific cDNAs (differ in exon 9 versus exon 10) with small C-terminal tags (FLAG, HA). Each isoform has the same catalytic architecture but different regulatory properties.
• Isoform-specific rescue: separate rescue with PKM1 (constitutively active tetramer) or PKM2 (allosterically regulated) enables comprehensive isoform-function studies.
• Allosteric mutant rescue: PKM2 K433E mutation disrupts FBP allosteric activation, useful for studying PKM2 regulation.
• Functional readout: rescue should restore pyruvate kinase activity and glycolytic flux; isoform-specific rescue reveals distinct metabolic and proliferation phenotypes.
A-549 transduces efficiently with lentivirus and supports systematic isoform-specific rescue experiments.
What are the application scenarios for this model?
Primary applications:
• PKM1 vs PKM2 isoform-specific rescue: separate rescue with PKM1 or PKM2 cDNAs enables comprehensive isoform-function studies in cancer metabolism context.
• Pyruvate kinase activity: cellular pyruvate kinase activity (lactate generation, ¹³C-glucose tracing) characterization.
• Warburg effect studies: glycolytic flux analysis (Seahorse ECAR) and metabolite levels under glucose-replete and -depleted conditions.
• PKM2 activator pharmacology: critical genetic control for TEPP-46, DASA-58, and other PKM2 tetramerization activators in cancer drug development.
EDITGENE recommends this model for researchers investigating cancer metabolism, Warburg effect mechanisms, and PKM2-targeted therapeutic development.
Which is better for studying PKM function, PKM Knockout A-549 Cell Line or PKM overexpression A-549 Cell Line?
The choice depends on whether you are studying PKM (pyruvate kinase muscle isoform)'s role in glycolysis or its functions as the principal Warburg-effect-associated PKM2 isoform in cancer. The Knockout line is the standard tool for asking whether PKM is required for cellular pyruvate generation — PKM produces two splice isoforms, PKM1 (constitutively active tetramer) and PKM2 (allosterically regulated, dimer-tetramer dynamic), with PKM2 predominating in cancer cells and supporting metabolic flexibility through reduced enzymatic activity. Overexpression is useful for studying isoform-specific PKM functions or for testing PKM2 activators.
Important consideration: PKM knockout eliminates both PKM1 and PKM2 isoforms — PKLR (liver-erythrocyte PK) provides limited compensation in non-hepatocyte contexts. For cancer metabolism research, the EDITGENE PKM Knockout in A-549 is highly relevant — A-549 is an NSCLC model expressing predominantly PKM2 isoform, and PKM2 is a validated cancer metabolic target. Rescue with isoform-specific cDNAs (PKM1 versus PKM2) enables comprehensive isoform-function studies. The knockout is a critical specificity control for PKM2 activators (TEPP-46, DASA-58) and PKM2-selective inhibitors in cancer drug development.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Related Publications
Mitochondrial PKM2 deacetylation by procyanidin B2-induced SIRT3 upregulation alleviates lung ischemia/reperfusion injury.
IF=9.6
Cell death & disease
Apoptosis is a critical event in the pathogenesis of lung ischemia/reperfusion (I/R) injury. Sirtuin 3 (SIRT3), an important deacetylase predominantly localized in mitochondria, regulates diverse physiological processes, including apoptosis. However, the detailed mechanisms by which SIRT3 regulates lung I/R injury remain unclear. Many polyphenols strongly regulate the sirtuin family. In this study, we found that a polyphenol compound, procyanidin B2 (PCB2), activated SIRT3 in mouse lungs. Due to this effect, PCB2 administration attenuated histological lesions, relieved pulmonary dysfunction, and improved the survival rate of the murine model of lung I/R injury. Additionally, this treatment inhibited hypoxia/reoxygenation (H/R)-induced A549 cell apoptosis and rescued Bcl-2 expression. Using Sirt3-knockout mice and specific SIRT3 knockdown in vitro, we further found that SIRT3 strongly protects against lung I/R injury. Sirt3 deficiency or enzymatic inactivation substantially aggravated lung I/R-induced pulmonary lesions, promoted apoptosis, and abolished PCB2-mediated protection. Mitochondrial pyruvate kinase M2 (PKM2) inhibits apoptosis by stabilizing Bcl-2. Here, we found that PKM2 accumulates and is hyperacetylated in mitochondria upon lung I/R injury. By screening the potential sites of PKM2 acetylation, we found that SIRT3 deacetylates the K433 residue of PKM2 in A549 cells. Transfection with a deacetylated mimic plasmid of PKM2 noticeably reduced apoptosis, while acetylated mimic transfection abolished the protective effect of PKM2. Furthermore, PKM2 knockdown or inhibition in vivo significantly abrogated the antiapoptotic effects of SIRT3 upregulation. Collectively, this study provides the first evidence that the SIRT3/PKM2 pathway is a protective target for the suppression of apoptosis in lung I/R injury. Moreover, this study identifies K433 deacetylation of PKM2 as a novel modification that regulates its anti-apoptotic activity. In addition, PCB2-mediated modulation of the SIRT3/PKM2 pathway may significantly protect against lung I/R injury, suggesting a novel prophylactic strategy for lung I/R injury.